Gland Pharma Key Ratios
NSE: GLAND | BSE: 543245
₹2,940.20
₹-21.70
(-0.73%)
As on 21-Sep-2026IST
Market cap
₹48,540 Cr
Revenue (TTM)
₹6,725 Cr
P/E Ratio
43
P/B Ratio
4.6
Div. Yield
0.7 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 1.99 | 23.85 | 15.86 | 9.62 | 5.16 |
| EBIT | -7.54 | 36.33 | 19.89 | 23.17 | 5.48 |
| Net Profit | -13.33 | 35.33 | 24.36 | 22.22 | 6.44 |
| EPS | -13.44 | 35.17 | 22.72 | 23.83 | 5.76 |
| Book Value | -- | -- | 12.70 | 9.01 | 11.74 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 31.17 | 21.62 | 19.59 | 18.75 | 15.86 |
| Net Margin
| 25.33 | 17.37 | 16.02 | 15.23 | 11.98 |
| Return on equity
| 12.20 | 11.32 | 11.51 | 10.56 | 7.82 |
| Return on Capital
| 16.57 | 15.89 | -- | 14.96 | 11.97 |
| Return on Assets
| 11.37 | 9.88 | 9.51 | 8.70 | 6.41 |
| Debt to Equity (x)
| -- | -- | 0.01 | 0.02 | 0.03 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
14.96
|
11.97
|
13.63
|
14.04
|
24.85
|
|
|
|||
|
Peer Median
|
--
|
14.32
|
12.19
|
11.06
|
9.85
|
8.65
|
|
|
|
|
|
ROE
11.51
Higher than Peers by 3.37
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
11.51
|
10.56
|
7.82
|
9.26
|
10.34
|
18.61
|
|
|
|||
|
Peer Median
|
8.14
|
11.24
|
9.26
|
7.17
|
7.54
|
3.52
|
|
|
|
|
|
ROA
9.51
Higher than Peers by 3.69
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
9.51
|
8.70
|
6.41
|
7.97
|
9.40
|
16.91
|
|
|
|||
|
Peer Median
|
5.82
|
6.00
|
7.65
|
3.78
|
3.99
|
2.87
|
|
|
|
|
|
EBIT Margin
19.59
Higher than Peers by 10.58
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
19.59
|
18.75
|
15.86
|
17.45
|
24.22
|
31.81
|
|
|
|||
|
Peer Median
|
9.01
|
21.37
|
--
|
12.49
|
13.66
|
32.74
|
|
|
|
|
|
Net Margin
16.02
Higher than Peers by 9.39
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
16.02
|
15.23
|
11.98
|
13.24
|
20.21
|
26.20
|
|
|
|||
|
Peer Median
|
6.63
|
6.14
|
5.63
|
2.96
|
2.70
|
2.53
|
|
|
|
|
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
22.56
|
19.16
|
19.72
|
25.60
|
30.04
|
|
|
|||
|
Peer Median
|
--
|
0.00
|
--
|
0.00
|
0.00
|
0.00
|
|
|
|
|
|
Revenue Growth
17.57
Higher than Peers by 2.90
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
17.57
|
14.50
|
-0.85
|
56.29
|
-17.64
|
27.08
|
|
|
|||
|
Peer Median
|
14.67
|
52.85
|
--
|
39.85
|
38.90
|
--
|
|
|
|
|
|
EBIT Growth
33.69
Higher than Peers by 17.14
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
33.69
|
35.33
|
-9.86
|
12.58
|
-37.28
|
16.32
|
|
|
|||
|
Peer Median
|
16.55
|
213.56
|
--
|
20.42
|
176.64
|
--
|
|
|
|
|
|
Net Profit Growth
24.36
Higher than Peers by 16.86
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
24.36
|
47.07
|
-9.57
|
-1.10
|
-35.54
|
21.54
|
|
|
|||
|
Peer Median
|
7.50
|
210.06
|
--
|
12.85
|
218.06
|
--
|
|
|
|
|
|
EPS Growth
22.72
Higher than Peers by 5.52
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
22.72
|
47.07
|
-9.60
|
-1.11
|
-35.70
|
21.01
|
|
|
|||
|
Peer Median
|
17.19
|
202.77
|
--
|
33.33
|
200.00
|
--
|
|
|
|
|
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
12.70
|
4.91
|
9.62
|
11.38
|
21.55
|
|
|
|||
|
Peer Median
|
Solvency
Debt to Equity
0.01
Higher than Peers by 0.01
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
0.01
|
0.02
|
0.03
|
0.04
|
0.00
|
0.00
|
|
|
|||
|
Peer Median
|
0.00
|
0.24
|
0.22
|
0.20
|
0.19
|
0.38
|
|
|
|
|
|
Current Ratio
4.68
Higher than Peers by 2.57
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
4.68
|
4.68
|
4.33
|
4.04
|
9.46
|
10.05
|
|
|
|||
|
Peer Median
|
2.11
|
2.03
|
1.99
|
2.03
|
1.95
|
1.92
|
|
|
|
|
|
Quick Ratio
3.60
Higher than Peers by 2.17
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
3.60
|
3.60
|
3.26
|
2.85
|
6.80
|
8.02
|
|
|
|||
|
Peer Median
|
1.43
|
5.42
|
--
|
1.12
|
1.24
|
5.88
|
|
|
|
|
|
Interest Coverage
61.70
Higher than Peers by 54.30
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
61.70
|
45.01
|
26.30
|
44.23
|
142.61
|
309.77
|
|
|
|||
|
Peer Median
|
7.40
|
3.95
|
4.14
|
2.98
|
3.48
|
2.73
|
|
|
|
|
|
Operating Efficiency
Debtors to sales
28.12
Higher than Peers by 2.22
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
28.12
|
29.41
|
27.00
|
27.52
|
24.04
|
24.42
|
|
|
|||
|
Peer Median
|
25.91
|
50.20
|
--
|
29.85
|
41.06
|
55.67
|
|
|
|
|
|
Asset Turnover
0.57
Lower than Peers by 0.18
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
0.57
|
0.54
|
0.52
|
0.58
|
0.44
|
0.61
|
|
|
|||
|
Peer Median
|
0.75
|
2.93
|
--
|
1.55
|
3.06
|
1.38
|
|
|
|
|
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
96.72
|
99.92
|
78.29
|
97.99
|
72.40
|
|
|
|||
|
Peer Median
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
97.32
|
108.54
|
116.00
|
157.65
|
102.05
|
|
|
|||
|
Peer Median
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
134.60
|
138.65
|
113.80
|
113.72
|
74.34
|
|
|
|||
|
Peer Median
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
--
|
59.43
|
69.81
|
80.48
|
141.92
|
100.11
|
|
|
|||
|
Peer Median
|
Valuation
Price / Earnings
43.00
Higher than Peers by 8.31
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
43.00
|
27.22
|
37.55
|
39.27
|
26.75
|
44.33
|
|
|
|||
|
Peer Median
|
34.69
|
36.19
|
44.20
|
39.23
|
34.42
|
43.43
|
|
|
|
|
|
Price / Book Value
4.57
Higher than Peers by 0.60
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
4.57
|
2.71
|
2.87
|
3.48
|
2.63
|
7.52
|
|
|
|||
|
Peer Median
|
3.97
|
2.04
|
2.96
|
2.56
|
2.03
|
1.76
|
|
|
|
|
|
Dividend Yield
0.68
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
0.68
|
1.18
|
1.13
|
1.09
|
--
|
--
|
|
|
|||
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
EV/EBITDA
21.93
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
21.93
|
12.77
|
16.15
|
19.17
|
13.54
|
29.19
|
|
|
|||
|
Peer Median
|
--
|
16.50
|
23.15
|
24.73
|
22.79
|
18.08
|
|
|
|
|
|
Market Cap
48,540
Higher than Peers by 48,469
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
Mar-17
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
48,540
|
27,965
|
26,233
|
30,338
|
20,894
|
53,712
|
|
|
|||
|
Peer Median
|
72
|
53
|
55
|
58
|
40
|
20
|
|
|
|
|
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
